Our competitive niche is early-stage commercial development of life sciences technologies. To generate investor value in this niche, we have developed a business model that represents a creative convergence of the distinctive aspects of existing models of early-stage commercialization-technology transfer, incubators, discovery-based medtech/biotech companies and venture capital.

We combine investment in and active management of a select technology portfolio with the flexibility to monetize our assets at various stages of clinical development. We partner with the inventors and appropriate collaborators to create a value proposition that benefits all parties, and seek to build each technology opportunity into a viable independent business that can achieve significant scientific and financial milestones. Our unique business model involves thoughtful integration at many levels-academic research with commercial development, technological innovation with clinical reality and validation, and financial investment with active development activity-in order to advance each innovation to a commercially viable or institutionally financeable stage and achieve optimal levels of appreciation at appropriately managed levels of risk.